The economy of scale is obviously one of the main
reasons this deal was done. You obviously have
just recently come aboard Mayne or you would
have been aware of Annovera years ago . During
all the hoopla of FDA for Nuvaring generic. Being
rejected on three occasions while then CEO said
we we’re learning. You appear quite ignorant of the
management of Mayne. The market is not so ignorant
. When you are spending other people’s money
your diligence factor is not on High Alert, like your
mown. Until this current leadership of Mayne earns
my respect I will remain hesitant. Unlike you !
Ann: MYX signs license agreement for women's health products, page-111
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |